[go: up one dir, main page]

WO2008033432A3 - Immunomodulation par des ribonucléosides et des oligoribonucléotides chimiquement modifiés - Google Patents

Immunomodulation par des ribonucléosides et des oligoribonucléotides chimiquement modifiés Download PDF

Info

Publication number
WO2008033432A3
WO2008033432A3 PCT/US2007/019873 US2007019873W WO2008033432A3 WO 2008033432 A3 WO2008033432 A3 WO 2008033432A3 US 2007019873 W US2007019873 W US 2007019873W WO 2008033432 A3 WO2008033432 A3 WO 2008033432A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligoribonucleotides
chemically modified
immune modulation
modified ribonucleosides
ribonucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019873
Other languages
English (en)
Other versions
WO2008033432A2 (fr
Inventor
Jorg Vollmer
Stefan Bauer
Grayson B Lipford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical GmbH
Coley Pharmaceutical Group Inc
Original Assignee
Coley Pharmaceutical GmbH
Coley Pharmaceutical Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical GmbH, Coley Pharmaceutical Group Inc filed Critical Coley Pharmaceutical GmbH
Publication of WO2008033432A2 publication Critical patent/WO2008033432A2/fr
Publication of WO2008033432A3 publication Critical patent/WO2008033432A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des oligoribonucléotides modifiés à activité immunomodulatrice. L'invention concerne le traitement de maladies auto-immunes ou infectieuses à l'aide des oligonucléotides de l'invention.
PCT/US2007/019873 2006-09-12 2007-09-12 Immunomodulation par des ribonucléosides et des oligoribonucléotides chimiquement modifiés Ceased WO2008033432A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84383806P 2006-09-12 2006-09-12
US60/843,838 2006-09-12

Publications (2)

Publication Number Publication Date
WO2008033432A2 WO2008033432A2 (fr) 2008-03-20
WO2008033432A3 true WO2008033432A3 (fr) 2008-11-06

Family

ID=39047781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019873 Ceased WO2008033432A2 (fr) 2006-09-12 2007-09-12 Immunomodulation par des ribonucléosides et des oligoribonucléotides chimiquement modifiés

Country Status (1)

Country Link
WO (1) WO2008033432A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NZ508927A (en) 1998-05-22 2003-12-19 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
DE60229422D1 (de) 2001-08-17 2008-11-27 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
NZ573064A (en) 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
DK2241325T3 (da) 2002-10-29 2012-04-10 Coley Pharm Group Inc Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
WO2004053104A2 (fr) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. Acides nucleiques 5'cpg et leurs methodes d'utilisation
EP1728863A3 (fr) 2003-10-30 2006-12-20 Coley Pharmaceutical GmbH Analogues d'oligonucléotides de classe C présentant des propriétés immunostimulatrices accrues
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
BRPI0618857B1 (pt) 2005-11-25 2022-07-19 Zoetis Belgium S.A Oligonucleotídeo de rna isolado, e método para regular negativamente células reguladoras cd4+ imunossupressoras
CN101517082B (zh) 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
CN102481375B (zh) 2009-05-27 2017-06-06 西莱克塔生物科技公司 具有不同释放速率的纳米载体加工组分
EA023897B1 (ru) 2009-08-26 2016-07-29 Селекта Байосайенсиз, Инк. Композиции, которые индуцируют хелперное действие т-клеток
JP6324067B2 (ja) 2010-05-26 2018-05-16 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 多価合成ナノキャリアワクチン
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
WO2012138846A2 (fr) * 2011-04-05 2012-10-11 The Regents Of The University Of California Procédé et compositions comprenant un agoniste et des antagonistes de petits arn pour moduler une inflammation
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
KR20150127206A (ko) 2013-03-14 2015-11-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 나노입자-기재 조성물
US9828641B2 (en) 2013-08-01 2017-11-28 The Regents Of The University Of California Systemic genotoxicity as blood marker for allergic inflammation
EP3556353A3 (fr) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Adjuvants de vaccins à nanoparticules lipidiques et systèmes d'administration d'antigènes
EA201692512A1 (ru) 2014-06-25 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
US10538769B2 (en) 2015-09-04 2020-01-21 Oregon State University Renal selective inhibition of cytochrome P450 3A5
US12365714B2 (en) 2018-03-05 2025-07-22 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
WO2019207066A1 (fr) * 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions destinés au traitement du syndrome de sjögren
CA3144902A1 (fr) 2019-08-14 2022-01-19 Andreas Thess Combinaisons d'arn et compositions a proprietes immunostimulatrices reduites
WO2024028794A1 (fr) 2022-08-02 2024-02-08 Temple Therapeutics BV Méthodes de traitement de troubles de l'endomètre et de l'hyperprolifération ovarienne

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20030232443A1 (en) * 2002-06-18 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of centromere protein B expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20030232443A1 (en) * 2002-06-18 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of centromere protein B expression

Also Published As

Publication number Publication date
WO2008033432A2 (fr) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008033432A3 (fr) Immunomodulation par des ribonucléosides et des oligoribonucléotides chimiquement modifiés
EP4435100A3 (fr) Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations
WO2004112687A3 (fr) Compositions et methodes antivirales
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
WO2009126688A8 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
MX2009011500A (es) Anticuerpos anti-mdl-1.
WO2009013543A3 (fr) Agents de liaisons ciblés dirigés vers kdr, et utilisations de ceux-ci - 035
WO2005079533A3 (fr) Procedes et compositions de mediation du silençage genique
WO2012083048A3 (fr) Composés anti-viraux
WO2008149353A3 (fr) Composés activant la télomérase et leurs procédés d'utilisation
EP1954788A4 (fr) Supports pour catalyseurs de combustion et leurs procedes d utilisation
WO2009121948A3 (fr) Anticorps à domaine unique capables de moduler une activité de la bace
WO2012083061A3 (fr) Composés anti-viraux
WO2010011331A3 (fr) Compositions et procédés se rapportant à la fonction sirt1
WO2008066784A3 (fr) Expression de foxp3 par des cellules cancéreuses
WO2012083058A3 (fr) Composés anti-viraux
WO2007106915A8 (fr) Anticorps à efgl 7 et leurs procédés d'utilisation
WO2010072740A3 (fr) Agents de liaison ciblés dirigés contre α5β1 et leurs applications
WO2007130616A3 (fr) Polyamides destinés au traitement du papillomavirus humain
WO2010052559A8 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament.
ZA200908525B (en) Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
WO2007011639A3 (fr) Immunoglobulines catalytiques
WO2007103584A3 (fr) Polyamides pour le traitement du virus du papillome humain
WO2010042633A3 (fr) Complexes de naringénine et méthodes d'utilisation associés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838130

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838130

Country of ref document: EP

Kind code of ref document: A2